JP2016531110A5 - - Google Patents

Info

Publication number

JP2016531110A5

JP2016531110A5 JP2016529806A JP2016529806A JP2016531110A5 JP 2016531110 A5 JP2016531110 A5 JP 2016531110A5 JP 2016529806 A JP2016529806 A JP 2016529806A JP 2016529806 A JP2016529806 A JP 2016529806A JP 2016531110 A5 JP2016531110 A5 JP 2016531110A5

Authority

JP

Japan

Prior art keywords

polypeptide

side chain

amide

ester

salt

Prior art date

2014-07-21

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 108090000765 processed proteins & peptides Proteins 0.000 claims 31
• 229920001184 polypeptide Polymers 0.000 claims 29
• 102000004196 processed proteins & peptides Human genes 0.000 claims 29
• 150000001408 amides Chemical class 0.000 claims 15
• 150000002148 esters Chemical class 0.000 claims 15
• 150000003839 salts Chemical class 0.000 claims 15
• LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 claims 7
• 210000004899 c-terminal region Anatomy 0.000 claims 4
• 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims 4
• 239000003814 drug Substances 0.000 claims 3
• 229940123338 Aldosterone synthase inhibitor Drugs 0.000 claims 2
• 101800000407 Brain natriuretic peptide 32 Proteins 0.000 claims 2
• 229940127291 Calcium channel antagonist Drugs 0.000 claims 2
• 206010007556 Cardiac failure acute Diseases 0.000 claims 2
• 150000001413 amino acids Chemical class 0.000 claims 2
• 239000000480 calcium channel blocker Substances 0.000 claims 2
• 239000003795 chemical substances by application Substances 0.000 claims 2
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
• 125000002228 disulfide group Chemical group 0.000 claims 2
• 239000002308 endothelin receptor antagonist Substances 0.000 claims 2
• 239000003087 receptor blocking agent Substances 0.000 claims 2
• 125000001431 2-aminoisobutyric acid group Chemical group [#6]C([#6])(N*)C(*)=O 0.000 claims 1
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
• ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical group OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 claims 1
• 108091008803 APLNR Proteins 0.000 claims 1
• 102000005666 Apolipoprotein A-I Human genes 0.000 claims 1
• 108010059886 Apolipoprotein A-I Proteins 0.000 claims 1
• 201000001320 Atherosclerosis Diseases 0.000 claims 1
• 206010003658 Atrial Fibrillation Diseases 0.000 claims 1
• 206010059027 Brugada syndrome Diseases 0.000 claims 1
• 206010007558 Cardiac failure chronic Diseases 0.000 claims 1
• 208000031229 Cardiomyopathies Diseases 0.000 claims 1
• 208000024172 Cardiovascular disease Diseases 0.000 claims 1
• FFFHZYDWPBMWHY-GSVOUGTGSA-N D-Homocysteine Chemical compound OC(=O)[C@H](N)CCS FFFHZYDWPBMWHY-GSVOUGTGSA-N 0.000 claims 1
• BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims 1
• 206010016807 Fluid retention Diseases 0.000 claims 1
• 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
• 102000008100 Human Serum Albumin Human genes 0.000 claims 1
• 108091006905 Human Serum Albumin Proteins 0.000 claims 1
• 206010020772 Hypertension Diseases 0.000 claims 1
• FFFHZYDWPBMWHY-UHFFFAOYSA-N L-Homocysteine Natural products OC(=O)C(N)CCS FFFHZYDWPBMWHY-UHFFFAOYSA-N 0.000 claims 1
• FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 claims 1
• 102000003979 Mineralocorticoid Receptors Human genes 0.000 claims 1
• 108090000375 Mineralocorticoid Receptors Proteins 0.000 claims 1
• 208000008589 Obesity Diseases 0.000 claims 1
• 208000005764 Peripheral Arterial Disease Diseases 0.000 claims 1
• 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims 1
• 102000003743 Relaxin Human genes 0.000 claims 1
• 108090000103 Relaxin Proteins 0.000 claims 1
• 206010042496 Sunburn Diseases 0.000 claims 1
• 208000032109 Transient ischaemic attack Diseases 0.000 claims 1
• 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
• ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 claims 1
• 230000008484 agonism Effects 0.000 claims 1
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
• 239000002333 angiotensin II receptor antagonist Substances 0.000 claims 1
• 229940126317 angiotensin II receptor antagonist Drugs 0.000 claims 1
• 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 1
• 230000003178 anti-diabetic effect Effects 0.000 claims 1
• 230000003579 anti-obesity Effects 0.000 claims 1
• 239000003146 anticoagulant agent Substances 0.000 claims 1
• 229940127219 anticoagulant drug Drugs 0.000 claims 1
• 239000003472 antidiabetic agent Substances 0.000 claims 1
• 206010003119 arrhythmia Diseases 0.000 claims 1
• 230000006793 arrhythmia Effects 0.000 claims 1
• 102000012740 beta Adrenergic Receptors Human genes 0.000 claims 1
• 108010079452 beta Adrenergic Receptors Proteins 0.000 claims 1
• 239000003354 cholesterol ester transfer protein inhibitor Substances 0.000 claims 1
• 229940125881 cholesteryl ester transfer protein inhibitor Drugs 0.000 claims 1
• 206010012601 diabetes mellitus Diseases 0.000 claims 1
• 201000010099 disease Diseases 0.000 claims 1
• 208000035475 disorder Diseases 0.000 claims 1
• 239000002934 diuretic Substances 0.000 claims 1
• 230000001882 diuretic effect Effects 0.000 claims 1
• 229940079593 drug Drugs 0.000 claims 1
• 239000003937 drug carrier Substances 0.000 claims 1
• 239000012634 fragment Substances 0.000 claims 1
• 208000004104 gestational diabetes Diseases 0.000 claims 1
• 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 1
• 239000003112 inhibitor Substances 0.000 claims 1
• 230000000302 ischemic effect Effects 0.000 claims 1
• HPNRHPKXQZSDFX-OAQDCNSJSA-N nesiritide Chemical compound C([C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 HPNRHPKXQZSDFX-OAQDCNSJSA-N 0.000 claims 1
• 229960001267 nesiritide Drugs 0.000 claims 1
• 235000020824 obesity Nutrition 0.000 claims 1
• 201000011461 pre-eclampsia Diseases 0.000 claims 1
• 230000002265 prevention Effects 0.000 claims 1
• 208000002815 pulmonary hypertension Diseases 0.000 claims 1
• 239000002461 renin inhibitor Substances 0.000 claims 1
• 229940086526 renin-inhibitors Drugs 0.000 claims 1
• 208000037803 restenosis Diseases 0.000 claims 1
• 201000010875 transient cerebral ischemia Diseases 0.000 claims 1
• 230000009529 traumatic brain injury Effects 0.000 claims 1
• 206010047302 ventricular tachycardia Diseases 0.000 claims 1